SMO

Across TCGA pan-cancer cohorts, SMO Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SMO data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher SMO Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SMO expression acts as an unfavorable survival marker.

MESO, BLCA, and BRCA are the cancer types where SMO Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.069	0.580	<.001	36	view →
BLCA	OS	Median	All	0.199	0.619	.003	26	view →
BRCA	OS	Median	III,IV	0.313	0.834	.004	12	view →
ESCA	OS	Median	II,III,IV	0.248	0.686	.019	9	view →
SCLC	OS	Median	III,IV	0.082	0.630	.001	6	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
SKCM	OS	Median	All	0.653	0.785	.015	4	view →
COAD	DFS	Median	All	0.156	0.521	.033	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SMO–MESO (OS)

Open the MESO breakdown →